D. Ross Camidge : rechercher sur Z-Library

Campagne de collecte 15 septembre 2024 – 1 octobre 2024 C'est quoi, la collecte de fonds?

Le plus grand référentiel d'articles scientifiques au monde. 70,000,000+ d'articles gratuitement.

Campagne de collecte 15 septembre 2024 – 1 octobre 2024

Z-Library est une des plus grandes bibliothèques en ligne dans le monde, avec le stockage de plus de 17,000,000 livres et plus de 84,837,000 articles. Nous encourageons l'accès libre de chacun à la littérature. Aujourd'hui (15 septembre 2024) nous faisons un appel de fonds à tous ceux qui veulent contribuer encore plus au soutien et au développement de notre projet.

Les téléchargements SANS LIMITE sont aussi (au cours de 31 jours après la date de don) disponibles pour TOUS les utilisateurs qui soient en mesure de soutenir le projet pendant la période de collecte de fonds jusqu'au 1 octobre 2024.

C'est quoi, la collecte de fonds?En savoir plus

Livres
Articles (169)
Les plus populaires
Liste
- Liste
- Tableau

1

Repotrectinib (TPX-0005) is a next generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent front mutations

Drilon, Alexander, Ou, Sai-Hong I., Cho, Byoung Chul, Kim, Dong-Wan, Lee, Jeeyun, Lin, Jessica J., Zhu, Viola W, Ahn, Myung-Ju, Camidge, D. Ross, Nguyen, Judy, Zhai, Dayong, Deng, Wei, Huang, Zhongdon

Journal:

Cancer Discovery

Année:

2018

Langue:

english

Fichier:

PDF, 5.57 MB

english, 2018

2

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Gomez, Daniel R., Tang, Chad, Zhang, Jianjun, Blumenschein, George R., Hernandez, Mike, Lee, J. Jack, Ye, Rong, Palma, David A., Louie, Alexander V., Camidge, D. Ross, Doebele, Robert C., Skoulidis, F

Journal:

Journal of Clinical Oncology

Année:

2019

Langue:

english

Fichier:

PDF, 709 KB

english, 2019

3

Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

Shaw, Alice T., Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S.W., Felip, Enriqueta, Chow, Laura Q.M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, B

Journal:

New England Journal of Medicine

Année:

2014

Langue:

english

Fichier:

PDF, 679 KB

english, 2014

4

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, Eunice L., Bang, Yung-Jue, Camidge, D. Ross, Shaw, Alice T., Solomon, Benjamin, Maki, Robert G., Ou, Sai-Hong I., Dezube, Bruce J., Jänne, Pasi A., Costa, Daniel B., Varella-Garcia, Marileila, K

Journal:

Boston Medical and Surgical Journal

Année:

2010

Langue:

english

Fichier:

PDF, 1.11 MB

english, 2010

5

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Peters, Solange, Camidge, D. Ross, Shaw, Alice T., Gadgeel, Shirish, Ahn, Jin S., Kim, Dong-Wan, Ou, Sai-Hong I., Pérol, Maurice, Dziadziuszko, Rafal, Rosell, Rafael, Zeaiter, Ali, Mitry, Emmanuel, Go

Journal:

New England Journal of Medicine

Année:

2017

Langue:

english

Fichier:

PDF, 291 KB

english, 2017

6

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Camidge, D. Ross, Dziadziuszko, Rafal, Peters, Solange, Mok, Tony, Noe, Johannes, Nowicka, Malgorzata, Gadgeel, Shirish M., Cheema, Parneet, Pavlakis, Nick, de Marinis, Filippo, Cho, Byoung Chul, Zhan

Journal:

Journal of Thoracic Oncology

Année:

2019

Langue:

english

Fichier:

PDF, 506 KB

english, 2019

7

Characterizing the phenomenon of radiation recall dermatitis

Ross Camidge, Allan Price

Journal:

Radiotherapy and Oncology

Année:

2001

Langue:

english

Fichier:

PDF, 102 KB

english, 2001

8

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

von Pawel, Joachim, Harvey, Jimmie H., Spigel, David R., Dediu, Mircea, Reck, Martin, Cebotaru, Cristina L., Humphreys, Robin C., Gribbin, Matthew J., Fox, Norma Lynn, Camidge, D. Ross

Journal:

Clinical Lung Cancer

Année:

2014

Langue:

english

Fichier:

PDF, 569 KB

english, 2014

9

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Camidge, D. Ross, Pao, William, Sequist, Lecia V.

Journal:

Nature Reviews Clinical Oncology (formerly Nature Clinical Practice Oncology)

Année:

2014

Langue:

english

Fichier:

PDF, 3.57 MB

english, 2014

10

Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer

Shaw, Alice T., Ou, Sai-Hong I., Bang, Yung-Jue, Camidge, D. Ross, Solomon, Benjamin J., Salgia, Ravi, Riely, Gregory J., Varella-Garcia, Marileila, Shapiro, Geoffrey I., Costa, Daniel B., Doebele, Ro

Journal:

New England Journal of Medicine

Année:

2014

Langue:

english

Fichier:

PDF, 673 KB

english, 2014

11

Response assessment criteria for brain metastases: proposal from the RANO group

Lin, Nancy U, Lee, Eudocia Q, Aoyama, Hidefumi, Barani, Igor J, Barboriak, Daniel P, Baumert, Brigitta G, Bendszus, Martin, Brown, Paul D, Camidge, D Ross, Chang, Susan M, Dancey, Janet, de Vries, Eli

Journal:

The Lancet Oncology

Année:

2015

Langue:

english

Fichier:

PDF, 1.60 MB

english, 2015

12

BM-32 * CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Shaw, A., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Ross Camidge, D., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Sa

Journal:

Année:

2014

Langue:

english

Fichier:

PDF, 31 KB

english, 2014

13

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Gomez, Daniel R, Blumenschein, George R, Lee, J Jack, Hernandez, Mike, Ye, Rong, Camidge, D Ross, Doebele, Robert C, Skoulidis, Ferdinandos, Gaspar, Laurie E, Gibbons, Don L, Karam, Jose A, Kavanagh,

Journal:

The Lancet Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 252 KB

english, 2016

14

Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer

Robin, Tyler P., Jones, Bernard L., Amini, Arya, Koshy, Matthew, Gaspar, Laurie E., Liu, Arthur K., Nath, Sameer K., Kavanagh, Brian D., Camidge, D. Ross, Rusthoven, Chad G.

Journal:

Année:

2018

Langue:

english

Fichier:

PDF, 298 KB

english, 2018

15

The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib

Patil, Tejas, Smith, Derek E., Bunn, Paul A., Aisner, Dara L., Le, Anh T., Hancock, Mark, Purcell, William T., Bowles, Daniel W., Camidge, D. Ross, Doebele, Robert C.

Journal:

Journal of Thoracic Oncology

Année:

2018

Langue:

english

Fichier:

PDF, 981 KB

english, 2018

16

A Phase 1 Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

Atrafi, Florence, Groen, Harry JM, Byers, Lauren Averett, Garralda, Elena, Lolkema, Martijn, Sangha, Randeep, Viteri, Santiago, Chae, Young Kwang, Camidge, D. Ross, Gabrail, Nashat, Hu, Beibei, Tian,

Journal:

Clinical Cancer Research

Année:

2018

Langue:

english

Fichier:

PDF, 1.67 MB

english, 2018

17

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Felip, Enriqueta, Soo, Ross A, Camidge, D Ross, Chiari, Rita, Bearz, Alessandra, Lin, Chia-Chi, Gadgeel, Shirish M, Riely, Gregory J, Tan, Eng Huat

Journal:

The Lancet Oncology

Année:

2018

Langue:

english

Fichier:

PDF, 1.30 MB

english, 2018

18

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

Ng, Terry L., Liu, Yiwei, Dimou, Anastasios, Patil, Tejas, Aisner, Dara L., Dong, Zhengwei, Jiang, Tao, Su, Chunxia, Wu, Chunyan, Ren, Shengxiang, Zhou, Caicun, Camidge, D. Ross

Journal:

Année:

2018

Langue:

english

Fichier:

PDF, 846 KB

english, 2018

19

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

Patil, Tejas, Pacheco, Jose M., Dimou, Anastasios, Purcell, William T., Rossi, Candice, Bunn, Paul A., Doebele, Robert C., Camidge, D. Ross, Ferrigno, Lisa

Journal:

Frontiers in Oncology

Année:

2020

Fichier:

PDF, 328 KB

2020

20

A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers

D. Ross Camidge, Dominic Smethurst, Jim Growcott, Nigel C. Barrass, John R. Foster, Salvatore Febbraro, Helen Swaisland, Andrew Hughes

Journal:

Cancer Chemotherapy and Pharmacology

Année:

2007

Langue:

english

Fichier:

PDF, 324 KB

english, 2007

21

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

D. Ross Camidge, Mike Pemberton, Jim Growcott, Dereck Amakye, David Wilson, Helen Swaisland, Cheryl Forder, Robert Wilkinson, Kate Byth, Andrew Hughes

Journal:

Cancer Chemotherapy and Pharmacology

Année:

2007

Langue:

english

Fichier:

PDF, 390 KB

english, 2007

22

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

Qing Zhou, Daniel Gustafson, Sujatha Nallapareddy, Sami Diab, Stephen Leong, Karl Lewis, Lia Gore, Wells A. Messersmith, Anthony M. Treston, S. Gail Eckhardt, Carolyn Sidor, D. Ross Camidge

Journal:

Investigational New Drugs

Année:

2011

Langue:

english

Fichier:

PDF, 185 KB

english, 2011

23

The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes

D. Ross Camidge, James J. Oliver, Carolyn Skinner, Ben Attwood, Fiona Nussey, Duncan Jodrell, David J. Webb

Journal:

British Journal of Clinical Pharmacology

Année:

2008

Langue:

english

Fichier:

PDF, 493 KB

english, 2008

24

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer

D. Ross Camidge, Mariana Theodoro, DeLee A. Maxson, Margaret Skokan, Tara O'Brien, Xian Lu, Robert C. Doebele, Anna E. Barón, Marileila Varella-Garcia

Journal:

Année:

2012

Langue:

english

Fichier:

PDF, 515 KB

english, 2012

25

Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer

Andrew J. Weickhardt, Micol S. Rothman, Smita Salian-Mehta, Katja Kiseljak-Vassiliades, Ana B. Oton, Robert C. Doebele, Margaret E. Wierman, D. Ross Camidge

Journal:

Année:

2012

Langue:

english

Fichier:

PDF, 452 KB

english, 2012

26

The intersection between cannabis and cancer in the United States

Daniel W. Bowles, Cindy L. O’Bryant, D. Ross Camidge, Antonio Jimeno

Journal:

Critical Reviews in Oncology/Hematology

Année:

2012

Langue:

english

Fichier:

PDF, 166 KB

english, 2012

27

The Potential of Death Receptor 4– and 5–Directed Therapies in the Treatment of Lung Cancer

D. Ross Camidge

Journal:

Clinical Lung Cancer

Année:

2007

Langue:

english

Fichier:

PDF, 2.09 MB

english, 2007

28

Tumour marker reference ranges and patients' anxiety

Max Dahele, Ross Camidge

Journal:

Année:

2003

Langue:

english

Fichier:

PDF, 53 KB

english, 2003

29

De Libris

Journal:

The Lancet Oncology

Année:

2002

Langue:

english

Fichier:

PDF, 129 KB

english, 2002

30

The European Organisation for Research and Treatment of Cancer

Journal:

The Lancet Oncology

Année:

2002

Langue:

english

Fichier:

PDF, 181 KB

english, 2002

31

Targeted manipulation of apoptosis in cancer treatment

Justin A Call, S Gail Eckhardt, D Ross Camidge

Journal:

The Lancet Oncology

Année:

2008

Langue:

english

Fichier:

PDF, 316 KB

english, 2008

32

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim, Ravi Salgia, Panagiotis Fidias, J

Journal:

The Lancet Oncology

Année:

2012

Langue:

english

Fichier:

PDF, 310 KB

english, 2012

33

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

Doebele, Robert C., Oton, Ana B., Peled, Nir, Camidge, D. Ross, Bunn, Paul A.

Journal:

Année:

2010

Langue:

english

Fichier:

PDF, 757 KB

english, 2010

34

The Rationale and Development of Therapeutic Insulin-like Growth Factor Axis Inhibition for Lung and Other Cancers

D. Ross Camidge, Rafal Dziadziuszko, Fred R. Hirsch

Journal:

Clinical Lung Cancer

Année:

2009

Langue:

english

Fichier:

PDF, 1.45 MB

english, 2009

35

Treating ALK-positive lung cancer—early successes and future challenges

Camidge, D. Ross, Doebele, Robert C.

Journal:

Nature Reviews Clinical Oncology (formerly Nature Clinical Practice Oncology)

Année:

2012

Langue:

english

Fichier:

PDF, 652 KB

english, 2012

36

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

D. Ross Camidge, Normand Blais, Derek J. Jonker…

Journal:

Cancer Chemotherapy and Pharmacology

Année:

2013

Langue:

english

Fichier:

PDF, 338 KB

english, 2013

37

Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer

Weickhardt, Andrew J., Aisner, Dara L., Franklin, Wilbur A., Varella-Garcia, Marileila, Doebele, Robert C., Camidge, D. Ross

Journal:

Année:

2013

Langue:

english

Fichier:

PDF, 332 KB

english, 2013

38

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group

Lin, Nancy U, Lee, Eudocia Q, Aoyama, Hidefumi, Barani, Igor J, Baumert, Brigitta G, Brown, Paul D, Camidge, D Ross, Chang, Susan M, Dancey, Janet, Gaspar, Laurie E, Harris, Gordon J, Hodi, F Stephen,

Journal:

The Lancet Oncology

Année:

2013

Langue:

english

Fichier:

PDF, 1.04 MB

english, 2013

39

Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis

Rusthoven, Kyle E., Hammerman, Susan F., Kavanagh, Brian D., Birtwhistle, Michael J., Stares, Mark, Camidge, D. Ross

Journal:

Acta Oncologica

Année:

2009

Langue:

english

Fichier:

PDF, 101 KB

english, 2009

40

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

Blais, Normand, Camidge, D. Ross, Jonker, Derek J., Soulières, Denis, Laurie, Scott A., Diab, Sami G., Ruiz-Garcia, Ana, Thall, Aron, Zhang, Ke, Chao, Richard C., Chow, Laura Q.

Journal:

Investigational New Drugs

Année:

2013

Langue:

english

Fichier:

PDF, 253 KB

english, 2013

41

Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib

Gan, Gregory N., Weickhardt, Andrew J., Scheier, Benjamin, Doebele, Robert C., Gaspar, Laurie E., Kavanagh, Brian D., Camidge, D. Ross

Journal:

International Journal of Radiation Oncology*Biology*Physics

Année:

2014

Langue:

english

Fichier:

PDF, 1.09 MB

english, 2014

42

Icotinib: kick-starting the Chinese anticancer drug industry

Camidge, D Ross

Journal:

The Lancet Oncology

Année:

2013

Langue:

english

Fichier:

PDF, 147 KB

english, 2013

43

Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Berge, Eamon M., Lu, Xian, Maxson, Delee, Barón, Anna E., Gadgeel, Shirish M., Solomon, Benjamin J., Doebele, Robert C., Varella-Garcia, Maria, Camidge, D. Ross

Journal:

Clinical Lung Cancer

Année:

2013

Langue:

english

Fichier:

PDF, 649 KB

english, 2013

44

Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib

Brosnan, Evelyn M., Weickhardt, Andrew J., Lu, Xian, Maxon, Delee A., Barón, Anna E., Chonchol, Michel, Camidge, D. Ross

Journal:

Année:

2014

Langue:

english

Fichier:

PDF, 520 KB

english, 2014

45

Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors

Camidge, D Ross

Journal:

Expert Opinion on Biological Therapy

Année:

2008

Langue:

english

Fichier:

PDF, 535 KB

english, 2008

46

Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer

Camidge, D. Ross, Skokan, Margaret, Kiatsimkul, Porntip, Helfrich, Barbara, Lu, Xian, Barón, Anna E., Schulte, Nathan, Maxson, DeLee, Aisner, Dara L., Franklin, Wilbur A., Doebele, Robert C., Varella-

Journal:

Année:

2013

Langue:

english

Fichier:

PDF, 481 KB

english, 2013

47

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib

Reckamp, Karen L., Giaccone, Giuseppe, Camidge, D. Ross, Gadgeel, Shirish M., Khuri, Fadlo R., Engelman, Jeff A., Koczywas, Marianna, Rajan, Arun, Campbell, Alicyn K., Gernhardt, Diana, Ruiz-Garcia, A

Journal:

Année:

2014

Langue:

english

Fichier:

PDF, 413 KB

english, 2014

48

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer

Levy, Benjamin, Spira, Alexander, Becker, Daniel, Evans, Tracey, Schnadig, Ian, Camidge, D. Ross, Bauman, Julie E., Hausman, Diana, Walker, Luke, Nemunaitis, John, Rudin, Charles M., Halmos, Balazs, B

Journal:

Journal of Thoracic Oncology

Année:

2014

Langue:

english

Fichier:

PDF, 772 KB

english, 2014

49

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

Camidge, D. Ross, Berge, Eamon M., Doebele, Robert C., Ballas, Marc S., Jahan, Thierry, Haigentz, Missak, Hoffman, David, Spicer, James, West, Howard, Lee, Pablo, Yang, Ling, Joshi, Adarsh, Gao, Ling,

Journal:

Journal of Thoracic Oncology

Année:

2014

Langue:

english

Fichier:

PDF, 488 KB

english, 2014

50

Crizotinib Effects on Creatinine and Non-Creatinine–Based Measures of Glomerular Filtration Rate

Camidge, D. Ross, Brosnan, Evelyn M., DeSilva, Chamath, Koo, Phillip J., Chonchol, Michel

Journal:

Journal of Thoracic Oncology

Année:

2014

Langue:

english

Fichier:

PDF, 479 KB

english, 2014